Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

2.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

3.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

4.

Alternative Medicine for Breast Cancer: Study Raises Concern

5.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot